



TEXAS DEPARTMENT OF STATE HEALTH SERVICES

JOHN HELLERSTEDT, M.D.
COMMISSIONER

P.O. Box 149347
Austin, Texas 78714-9347
1-888-963-7111
TTY: 1-800-735-2989
www.dshs.state.tx.us

August 05, 2016

Re: Updated Recommendations for Use of Serogroup B Meningococcal Vaccines

Dear Texas Vaccines for Children Providers,

In June 2016, the Advisory Committee on Immunization Practices (ACIP) voted to uphold their existing recommendation regarding the use of all meningococcal B (MenB) vaccines despite changes to Food and Drug Administration (FDA) labeling for the Trumenba® vaccines. MenB vaccines are recommended for use in groups of persons aged 10 years and older who are at increased risk for serogroup B meningococcal disease. MenB vaccines can also be used in adolescents and young adults, with the preferred administration age of 16 – 18 years. This recommendation will be reevaluated by the ACIP in October 2016.

Please note that the ACIP does not recommend the routine use of MenB vaccines in place of quadrivalent meningococcal vaccination.

Full recommendations are in the October 23, 2015 CDC Morbidity and Mortality Weekly Report (MMWR) at <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6441a3.htm>.

MenB vaccines are available for order through the Texas Vaccines for Children (TVFC) Program. MenB vaccines may be administered to eligible children and adolescents identified to be at high-risk, in addition to adolescents aged 16 – 18 years under the open recommendation. Bexsero® is approved as a two dose (0.5mL) series administered intramuscularly (IM) at least one month apart.

Although the package insert for Trumenba® indicates an approval as a two or three dose series, the ACIP recommends the use of a three dose (0.5mL) series administered IM on a 0-, 2-, and 6-month schedule. The series schedule for Trumenba will be reevaluated in October 2016. TVFC providers are expected to use all MenB vaccines as recommended by the ACIP; therefore, Trumenba® should only be administered as a three dose series until additional ACIP recommendations are available.

Additional information can be found in the Vaccine Advisory Number 27 located here: <http://www.dshs.texas.gov/immunize/vacadvise/default.shtm>. For more information about the TVFC Program, please visit www.dshs.state.tx.us/immunize/tvfc/tvfc_about.shtm.

Thank you for your continued support of the TVFC Program. If you have any questions, please contact the appropriate DSHS Health Service Region listed below.

| PINS Beginning With | Health Service Region | Phone Number |
|--|-----------------------|--------------|
| 1 | HSR 1 | 806-783-6412 |
| 2 | HSR 2 | 325-795-5660 |
| 3 | HSR 3 | 817-264-4790 |
| 04 or 05 not in Hardin, Jefferson or Orange Counties | HSR 4/5N | 903-533-5310 |
| 05 in Hardin, Jefferson or Orange Counties, 06 or 25 | HSR 6/5S | 713-767-3410 |
| 7 | HSR 7 | 254-778-6744 |
| 08 or 00 | HSR 8 | 210-949-2067 |
| 9 | HSR 9 | 432-571-4137 |
| 10 | HSR 10 | 915-834-7924 |
| 11 | HSR 11 | 956-421-5552 |

Sincerely,



Barbara Vassell
Manager, Vaccine Operations Group
Immunization Unit